Search our Database of Scientific Publications and Authors

I’m looking for a

    29702 results match your criteria Graft Versus Host Disease

    1 OF 595

    Therapeutic outcomes of haploidentical allogeneic hematopoietic stem cell transplantation in patients with severe aplastic anemia: a multicenter study.
    Transplantation 2018 Apr 19. Epub 2018 Apr 19.
    Southern Medical University, Guangzhou, China.
    Background: Haploidentical donor allogeneic hematopoietic stem cell transplantation (HID-HSCT) is an alternative curative treatment for patients with severe aplastic anemia (SAA) who do not have suitable matched related donors (MRD). The aim of this study was to compare the therapeutic outcomes of HID-HSCT with those of MRD-HSCT for SAA.

    Methods: A total of 235 SAA patients who underwent HID-HSCT (116) or MRD-HSCT (119) at 11 transplantation centers from January 2007 to January 2016 were included. Read More

    Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation.
    Front Med 2018 Apr 19. Epub 2018 Apr 19.
    Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.
    Human leukocyte antigen (HLA)-matched donors for hematopoietic stem cell transplantation (HSCT) have long been scarce in China. Haploidentical (haplo) donors are available for the vast majority of patients, but toxicity has limited this approach. Three new approaches for haplo-HSCT originated from Italy, China, and USA in 1990 and have been developed to world-renowned system up to now. Read More

    Allogeneic Stem Cell Transplantation in Fanconi Anemia and other inherited bone marrow failure disorders.
    Curr Drug Targets 2018 Apr 19. Epub 2018 Apr 19.
    Hopitaux de Paris, Hospital Saint-Louis, Paris. France.
    Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for patients with an inherited bone marrow failure syndrome (IBMFS). However, the risk of treatment-related mortality after HSCT is relatively high, with graft-versus host disease (GvHD) accounting for most of the transplant-related deaths. IBMF syndromes are rare, and case reports and small series in the literature illustrate highly heterogeneous practices in terms of indications for HSCT-, timing-, stem cell source and conditioning regimens. Read More

    Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease.
    Front Immunol 2018 4;9:656. Epub 2018 Apr 4.
    Developmental and Molecular Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
    Murine chronic graft-versus-host-disease (cGvHD) induced by injection of parental lymphocytes into F1 hybrids results in a disease similar to systemic lupus erythematosus. Here, we have used DBA/2 T cell injection into (C57BL/6 × DBA/2)F1 (BDF1) mice as a model system to test the prophylactic and therapeutic effects of interleukin-2 (IL-2)/anti-IL-2 immune complexes on the course of cGvHD. Our findings demonstrate that pretreatment with Treg inducing JES6/IL-2 complexes render BDF1 mice largely resistant to induction of cGvHD, whereas pretreatment with CD8 T cell/NK cell inducing S4B6/IL-2 complexes results in a more severe cGvHD. Read More

    Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease.
    Bone Marrow Transplant 2018 Apr 18. Epub 2018 Apr 18.
    Blood & Marrow Transplant & Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
    Glucocorticoids for primary therapy of acute GVHD have limited responses. A phase I/II trial tested 4 weeks of deacetylase inhibitor panobinostat started within 48 h of glucocorticoids (1 mg/kg/day prednisone or equivalent) as primary treatment for patients with either classic acute GVHD (n = 16) or acute GVHD overlapping with chronic (n = 6). Four patients received 2. Read More

    AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation.
    Bone Marrow Transplant 2018 Apr 18. Epub 2018 Apr 18.
    Chaim Sheba Medical Center, Tel-Hashomer, EBMT Paris Study Office, Israel, France.
    Acute myeloid leukemia with inv(3)(q21;q26.2)/t(3;3)(q21;q26.2) (3q26 AML) is a rare disease with poor prognosis and median survival of <1 year. Read More

    Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study.
    Clin J Am Soc Nephrol 2018 Apr 18. Epub 2018 Apr 18.
    Division of Pediatrics and Medicine, University of Washington, Clinical Research Division.
    Background And Objectives: Kidney injury is a significant complication for patients undergoing hematopoietic cell transplantation (HCT), but few studies have prospectively examined changes in GFR in long-term survivors of HCT. We described the association between changes in GFR and all-cause mortality in patients up to 10 years after HCT.

    Design, Setting, Participants, & Measurements: We conducted a prospective, observational cohort study of adult patients undergoing HCT at the Fred Hutchinson Cancer Center in Seattle, Washington from 2003 to 2015. Read More

    Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom.
    Health Qual Life Outcomes 2018 Apr 18;16(1):66. Epub 2018 Apr 18.
    Pfizer Inc, 445 Eastern Point Road, MS 8260-2502, Groton, CT, 06340, USA.
    Background: Health state (HS) utility values for patients with acute myeloid leukemia (AML), a hematological malignancy, are not available in the United Kingdom (UK). This study aims to develop clinically sound HSs for previously untreated patients with AML and to assign utility values based on preferences of the general UK population.

    Methods: This study was conducted in the UK and comprised 2 stages. Read More

    A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.
    Transpl Infect Dis 2018 Apr 18:e12906. Epub 2018 Apr 18.
    Bone Marrow Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy.
    Background: Invasive fungal infections (IFI) represent a common side effect of allogeneic hematopoietic stem cell transplant (allo-SCT), resulting in increased non relapse mortality (NRM) and reduced overall survival (OS) rates. 75-days of Fluconazole 400 mg/day represents the standard primary antifungal prophylaxis (PAP) after allo-SCT, especially for low-risk transplants. However, the ideal dosage of fluconazole has never been tested. Read More

    Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients.
    Pediatr Blood Cancer 2018 Apr 18:e27091. Epub 2018 Apr 18.
    Department of Pediatrics, Maria Fareri Children's Hospital at Westchester Medical Center, New York Medical College, Valhalla, New York.
    Background: The optimal dose and schedule of mycophenolate mofetil (MMF) in pediatric allogeneic stem cell transplant recipients remains to be determined. We previously reported safety and pharmacokinetics of MMF at 900 mg/m q6h dosing. This study was conducted to investigate the efficacy of tacrolimus plus q8h MMF dosing for acute graft versus host disease (GVHD) prophylaxis in a heterogeneous population of children, adolescent, young adult allogeneic stem cell transplant recipients, utilizing multiple allogeneic donor sources. Read More

    [The Effect of Serum Cytokine Levels prior Transplantation on the Outcome of Severe Aplastic Anemia Patients Received Allogeneic Hematopoietic Stem Cell Transplantation].
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 2018 Apr;26(2):502-507
    Institute of Hematology and Blood Diseases Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College,Tianjin 300020, China.
    Objective: To identify the role of serum cytokine levels prior allogeneic hematopoietic stem cell trans-plantation (allo-HSCT) in the outcome of severe aplastic anemia (SAA) patients received allo-HSCT treatment.

    Methods: The clinical data of 117 SAA patients received allo-HSCT were enrolled in this study. The overall survival (OS), graft versus host disease (GVHD) incidence and relationship of serum cytokines with OS and major transplantation complications were retrospectively analyzed. Read More

    [Clinical Analysis of Refractory Primary Central Nervouse System Lymphoma Treated with High-Dose MTX-Based Chemotherapy and Haploidentical Hematopoietic Stem Cell Infusion].
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 2018 Apr;26(2):432-436
    Department of Hematology, The General Hospital of the PLA Rocket Force, Beijing 100088, China.
    Objective: To investigate the efficacy and safety of high-dose methotrexate-based chemotherapy combined with granulocyte-colony stimulating factor (G-CSF)-mobilized family related haploidentical donor peripheral blood hematopoietic stem cell (G-PBHSC) infusion for the treatment of patients with refractory primary central nervouse system lymphoma (PCNSL).

    Methods: Three patients with refractory PCNSL were treated in Department of Hematology of the General Hospital of the PLA's Rocket Force from March 2014 to September 2015. The sex ratio of male to female was 1:2 and the median age was 54(48-66)years old. Read More

    Short-term Assessment of HSCT Effects on the Hypothalamus-Pituitary Axis in Pediatric Thalassemic Patients.
    Arch Iran Med 2018 Feb 1;21(2):56-60. Epub 2018 Feb 1.
    Hematology-Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, Iran.
    Background: Beta thalassemia major (BTM) and its treatment by hematopoietic stem cell transplantation (HSCT) may have deleterious effects on the endocrine systems. We assessed endocrine complications of HSCT in pediatric patients for 3 months.

    Methods: In 20 (6 female) pediatric major thalassemic patients (mean age of 10. Read More

    Vitiligo type cutaneous manifestation of chronic graft-versus-host disease. Case report.
    Rev Chil Pediatr 2018 Feb;89(1):113-117
    Departamento de Anatomía Patológica, Hospital Dr. Luis Calvo Mackenna, Santiago, Chile.
    Introduction: Graft-versus-host disease (GVHD) is caused by a pathologic and destructive response of the organism as a result of the interaction between donor immunocompetent T lymphocytes and the recipient tisular antigens. It's considered the most serious complication of hematopoietic stem cell transplantation, most frequently described after bone marrow transplantation (BMT). The skin is usually the first and most commonly affected organ, in both acute and chronic, with a variable clinical spectrum of presentation. Read More

    Efficacy of D- red blood cell transfusion and rituximab therapy in autoimmune hemolytic anemia with anti-D and panreactive autoantibodies arising after hematopoietic stem cell transplant.
    Transfusion 2018 Apr 17. Epub 2018 Apr 17.
    Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan.
    Background: Autoimmune hemolytic anemia (AIHA) is caused by autoantibodies to red blood cells (RBCs), which can be panreactive and/or specific to Rh/other blood group antigens. We report a severe case of AIHA after bone marrow transplantation (BMT) due to autoanti-D triggered by reactivation of Epstein-Barr virus (EBV) infection. A combined strategy of D- RBC transfusion and administration of anti-CD20 monoclonal antibody (MoAb) resolved the hemolysis. Read More

    Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia.
    Bone Marrow Transplant 2018 Apr 16. Epub 2018 Apr 16.
    Acute Leukemia Working Party of EBMT, Paris, France.
    Refined graft-versus-host disease (GVHD)/relapse-free survival (GRFS) considers main outcomes of allogeneic stem cell transplant (HSCT), estimating long-term survival without significant morbidity as a surrogate of HSCT success. We compared GRFS in 5059 adults with acute myeloid leukemia (AML), undergoing HSCT in first complete remission from 2000 to 2015 either from a matched sibling (MSD, n = 3731) or unrelated donor (MUD, n = 1328). Median age was 49 (range: 18-76) years. Read More

    Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review.
    Transplant Proc 2018 Apr;50(3):959-963
    Department of Hematology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China. Electronic address:
    The presence of recurrent gene mutations is increasingly important in acute myeloid leukemia (AML) and sheds new insights into the understanding of leukemogenesis, prognostic evaluation, and clinical therapeutic efficacy. Until now, ten-eleven translocation 2 (TET2) and isocitrate dehydrogenase 2 (IDH2) mutations were reported to be mutually exclusive in AML patients. Similarly, nucleophosmin (NPM1) and additional sex comb-like 1 (ASXL1) mutations were rarely coexisted in AML. Read More

    Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.
    J Hematol Oncol 2018 Apr 16;11(1):55. Epub 2018 Apr 16.
    ALWP office, Hôpital Saint-Antoine, Paris, France.
    Background: Acute myeloid leukemia (AML) is both more common and with more biologically aggressive phenotype in the elderly. Allogenic stem cell transplantation (allo-SCT) is the best treatment option in fit patients. Either HLA-matched unrelated donor (MUD) or haploidentical (Haplo) donor are possible alternative for patients in need. Read More

    Does matching for SNPs in the MHC gamma block in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant improve outcomes?
    Hum Immunol 2018 Apr 13. Epub 2018 Apr 13.
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA. Electronic address:
    Background: Matching at the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci is important in donor selection for patients undergoing unrelated allogeneic hematopoietic stem cell transplantation (ASCT). Additional matching across the MHC gamma region may further improve outcomes.

    Methods: The MHC gamma region was retrospectively genotyped in 66 adult recipients of ASCT and their 10/10 matched unrelated donors. Read More

    IMPDH Pharmacogenetics in Hematopoietic Cell Transplantation Patients.
    Biol Blood Marrow Transplant 2018 Apr 12. Epub 2018 Apr 12.
    School of Medicine, University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    We evaluated inosine monophosphate dehydrogenase (IMPDH) 1 and IMPDH2 pharmacogenetics in 247 recipient-donor pairs after nonmyeloablative hematopoietic cell transplant (HCT) recipients. Patients were conditioned with total body irradiation + fludarabine, received grafts from related or unrelated donors (10% HLA mismatch), with post-graft immunosuppression of mycophenolate mofetil (MMF) with a calcineurin inhibitor. Recipient and donor IMPDH genotype (rs11706052, rs2278294, rs2278293) were not associated with day 28 T-cell chimerism, acute graft versus host disease, disease relapse, cytomegalovirus reactivation, non-relapse mortality, or overall survival. Read More

    Early initiation of extracorporeal photochemotherapy increases response for chronic graft versus host disease following steroid failure.
    Transfus Clin Biol 2018 Apr 11. Epub 2018 Apr 11.
    Department of Hematology, Ankara University Medical School, Ankara, Turkey.
    Objectives: Chronic graft versus host disease (GVHD) is one of the major obstacles to achieve success in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Extracorporeal photochemotherapy (ECP) has been demonstrated to be an effective modality for the treatment of GVHD in previous studies but they vary in terms of initiation and duration. Our aim is to demonstrate the characteristics of our patients who received ECP for chronic GVHD to clarify the best treatment scheme. Read More

    The tolerogenic role of IFN-γ.
    Cytokine Growth Factor Rev 2018 Apr 7. Epub 2018 Apr 7.
    Blood Transfusion Centre of Slovenia, Department for Diagnostic Services, Šlajmerjeva 6, 1000, Ljubljana, Slovenia. Electronic address:
    Due to its extremely pleiotropic nature, the complex effects of IFN-γ exerted both on immune and non-immune cell types still remain only partially understood. The longstanding view of IFN-γ as being a predominantly inflammatory cytokine is constantly challenged by increasing demonstrations of its direct or indirect regulatory roles. Interferon-γ can exert tolerogenic effects on both innate and adaptive immune cell types, promoting tolerance of various antigen-presenting cells, and augmenting function and differentiation of regulatory T cells, respectively. Read More

    Varicella Zoster Virus Reactivation in Adult Survivors of Hematopoietic Cell Transplantation: How Do We Best Protect Our Patients?
    Biol Blood Marrow Transplant 2018 Apr 10. Epub 2018 Apr 10.
    Department of Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
    Reactivation of varicella zoster virus (VZV) remains a significant public health burden for long-term survivors of hematopoietic cell transplantation. Delayed immune reconstitution after transplantation due to immunosuppression, posttransplant therapies, poor engraftment, and graft-versus-host disease leave a large number of patients at risk for herpes zoster (shingles) and its highly morbid complications. Although prophylaxis with acyclovir or valacyclovir has reduced the incidence of VZV reactivation as long as prophylaxis is continued, the incidence of disease in the late posttransplant period or after stopping prophylaxis is greater in the HCT population than the general public. Read More

    Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies.
    Clin Nutr 2018 Mar 28. Epub 2018 Mar 28.
    Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.
    Background: Allogeneic haematopoietic cell transplantation (HCT) is often associated with poor oral intake due to painful mucositis and gastrointestinal sequalae that occur following a preparative regimen of intensive chemotherapy and/or total body radiation. Although attractive to assume that optimal nutrition improves HCT outcomes, there are limited data to support this. It is also unclear whether artificial nutrition support should be provided as enteral tube feeding or parenteral nutrition (PN). Read More

    Which donor is better when a matched donor is not available domestically? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population.
    Leuk Res 2018 Apr 4;69:31-38. Epub 2018 Apr 4.
    Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea. Electronic address:
    A substantial proportion of patients requiring allogeneic stem cell transplantation (alloSCT) do not have a human leukocyte antigen-matched sibling donor and need an alternative donor. In this multicenter retrospective study, we compared the outcomes of 176 patients with myelodysplastic syndrome and acute leukemia undergoing alloSCT from haploidentical (n = 121) and international (n = 55) donors between 2002 and 2016. For recipients of haploidentical and international donors, the 2-year overall survival rates were 33. Read More

    The glucocorticoid receptor in recipient cells keeps cytokine secretion in acute graft-versus-host disease at bay.
    Oncotarget 2018 Mar 2;9(21):15437-15450. Epub 2018 Mar 2.
    Institute for Cellular and Molecular Immunology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany.
    Graft-versus-host disease (GvHD) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT), which is caused by allogeneic T cells recognizing molecules of the recipient as foreign. Endogenous glucocorticoids (GC) released from the adrenal gland are crucial in regulating such inflammatory diseases. Here we demonstrate that genetically engineered mice, that are largely unresponsive to GC, suffer from aggravated clinical symptoms and increased mortality after HSCT, effects that could be tempered by neutralization of IL-6. Read More

    CD83 Antibody Inhibits Human B Cell Responses to Antigen as well as Dendritic Cell-Mediated CD4 T Cell Responses.
    J Immunol 2018 Apr 11. Epub 2018 Apr 11.
    Mater Research Institute, University of Queensland, Brisbane, Queensland 4102, Australia; and
    Anti-CD83 Ab capable of Ab-dependent cellular cytotoxicity can deplete activated CD83 human dendritic cells, thereby inhibiting CD4 T cell-mediated acute graft-versus-host disease. As CD83 is also expressed on the surface of activated B lymphocytes, we hypothesized that anti-CD83 would also inhibit B cell responses to stimulation. We found that anti-CD83 inhibited total IgM and IgG production in vitro by allostimulated human PBMC. Read More

    Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
    Front Immunol 2018 26;9:594. Epub 2018 Mar 26.
    State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China.
    There is now compelling evidence that tumor necrosis factor (TNF)-TNF receptor type II (TNFR2) interaction plays a decisive role in the activation, expansion, and phenotypical stability of suppressive CD4Foxp3 regulatory T cells (Tregs). In an effort to translate this basic research finding into a therapeutic benefit, a number of agonistic or antagonistic TNFR2-targeting biological agents with the capacity to activate or inhibit Treg activity have been developed and studied. Recent studies also show that thalidomide analogs, cyclophosphamide, and other small molecules are able to act on TNFR2, resulting in the elimination of TNFR2-expressing Tregs. Read More

    Donor Telomere Length and Causes of Death after Unrelated Hematopoietic Cell Transplant in Patients with Marrow Failure.
    Blood 2018 Apr 9. Epub 2018 Apr 9.
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
    Previous studies suggest that longer donor leukocyte telomere length (TL) is associated with improved survival after hematopoietic cell transplant (HCT) in severe aplastic anemia (SAA). This study aimed to determine whether cell-specific lymphocyte TL are associated with certain post-HCT causes of death. We used flow cytometry and fluorescence in situ hybridization (flow FISH) to measure TL in donor total lymphocytes and subsets: naïve enriched T-cells (CD45RA+CD20-), memory enriched T-cells (CD45RA-CD20-), NK-fully differentiated T cells (CD45RA+CD57+), and B cells (CD45RA+CD20+). Read More

    Recipient mucosal-associated invariant T cells control GVHD within the colon.
    J Clin Invest 2018 Apr 9. Epub 2018 Apr 9.
    Bone Marrow Transplantation Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
    Mucosal-associated invariant T (MAIT) cells are a unique innate-like T cell subset that responds to a wide array of bacteria and yeast through recognition of riboflavin metabolites presented by the MHC class I-like molecule MR1. Here, we demonstrate using MR1 tetramers that recipient MAIT cells are present in small but definable numbers in graft-versus-host disease (GVHD) target organs and protect from acute GVHD in the colon following bone marrow transplantation (BMT). Consistent with their preferential juxtaposition to microbial signals in the colon, recipient MAIT cells generate large amounts of IL-17A, promote gastrointestinal tract integrity, and limit the donor alloantigen presentation that in turn drives donor Th1 and Th17 expansion specifically in the colon after BMT. Read More

    The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.
    Expert Rev Clin Immunol 2018 Apr 19:1-16. Epub 2018 Apr 19.
    a Department of Pediatrics , Indiana University , Indianapolis , IN , USA.
    Introduction: Chronic graft-versus-host disease (cGVHD) continues to be the leading cause of late morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT), which is an increasingly applied curative method for both benign and malignant hematologic disorders. Biomarker identification is crucial for the development of noninvasive and cost-effective cGVHD diagnostic, prognostic, and predictive test for use in clinic. Furthermore, biomarkers may help to gain a better insight on ongoing pathophysiological processes. Read More

    [Development of the next generation humanized mouse for drug discovery].
    Nihon Yakurigaku Zasshi 2018 ;151(4):160-165
    Central Institute for Experimental Animals.
    A humanized mouse, which is efficiently engrafted human cells and tissues, is an important tool to mimic human physiology for biomedical researches. Since 2000s, severe combined immunodeficient mouse strains such as NOG, BRG, and NSG mice have been generated. They are great recipients to create humanized mouse models compared to previous other immunodeficient strains due to their multiple dysfunctions of innate and acquired immunity. Read More

    Ocular chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in an Italian referral center.
    Ocul Surf 2018 Apr 3. Epub 2018 Apr 3.
    Department of Ophthalmology, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy.
    Purpose: This study aimed to assess the prevalence and clinical manifestations of ocular graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

    Methods And Methods: 269 patients who received allo-HSCT for hematologic malignancies were evaluated between December 2013 and April 2017 in this prospective observational study. Subjects underwent ophthalmologic examination at 6, 12 and 24 months after allo-HSCT. Read More

    Biomarkers for post-transplantation outcomes.
    Blood 2018 Apr 5. Epub 2018 Apr 5.
    Departments of Pediatrics and Microbiology Immunology, and Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United States
    During the last decade, the development of biomarkers for the complications seen after allogeneic hematopoietic stem cell transplantation (allo-HSCT) has expanded tremendously with the most progress been made for acute graft-versus-host disease (aGVHD), a common and often fatal complication. Although many factors are known to determine transplant outcome (including the age of the recipient, comorbidity, conditioning intensity, donor source, donor-recipient human leukocyte antigen (HLA) compatibility, conditioning regimen, post-transplant GVHD prophylaxis), they are incomplete guides for predicting outcomes. Thanks to the advances in genomics, transcriptomics, proteomics and cytomics technologies, blood biomarkers have been identified and validated for us in promising diagnostic tests, prognostic tests stratifying for future occurrence of aGVHD, and predictive tests for responsiveness to GVHD therapy and non-relapse mortality. Read More

    Mesenchymal stromal cell exosome-enhanced regulatory T-cell production through an antigen-presenting cell-mediated pathway.
    Cytotherapy 2018 Apr 2. Epub 2018 Apr 2.
    Institute of Medical Biology, A*STAR, Singapore; Department of Surgery, YLL School of Medicine, NUS, Singapore. Electronic address:
    Background Aims: The immunomodulatory property of mesenchymal stromal cell (MSC) exosomes is well documented. On the basis of our previous report that MSC exosomes increased regulatory T-cell (Treg) production in mice with allogenic skin graft but not in ungrafted mice, we hypothesize that an activated immune system is key to exosome-mediated Treg production.

    Methods: To test our hypothesis, MSC exosomes were incubated with mouse spleen CD4 T cells that were activated with either anti-CD3/CD28 mAbs or allogenic antigen-presenting cell (APC)-enriched spleen CD11c cells to determine whether production of mouse CD4CD25 T cells or CD4CD25Foxp3 Tregs could be induced. Read More

    Posttransplant Cyclophosphamide for HLA-haploidentical Transplantation in Patients With Mucopolysaccharidosis.
    J Pediatr Hematol Oncol 2018 Apr 4. Epub 2018 Apr 4.
    Department of hematology and oncology, hospital of Capital Institute of Pediatrics, Chaoyang District, Beijing, China.
    We successfully used a haploidentical transplantation protocol with posttransplant cyclophosphamide (CY) (50 mg/kg/d on days +3 and +4) for in vivo T-cell depletion in patients with mucopolysaccharidosis using reduced-intensive conditioning regimens, followed by a busulfan-based conditioning regimen, which included busulfan (12 to 16 mg/kg) and fludarabine(150 to 200 mg/m)+rabbit antihuman thymocyte globulin (7.5 to 10 mg/kg) as a conditioning regimen. Cyclosporine or tacrolimus, methotrexate, mycophenolate mofetil, and methylprednisolone were administered to prevent graft-versus-host disease (GVHD). Read More

    EBV-PTLD, Adenovirus, and CMV in Pediatric Allogeneic Transplants With Alemtuzumab as Part of Pretransplant Conditioning: A Retrospective Single Center Study.
    J Pediatr Hematol Oncol 2018 Apr 3. Epub 2018 Apr 3.
    Division of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, MN.
    The risk of viral infections and reactivation occurring in the setting of pediatric allogeneic hematopoietic stem cell transplantation is a concern in the pediatric patient, especially with the use of Alemtuzumab (Campath) as a conditioning agent. The purpose of this study was to determine the incidence of Epstein-Barr virus posttransplant lymphoproliferative disorder (EBV-PTLD), cytomegalovirus (CMV), and adenovirus among pediatric recipients of alemtuzumab at our institution. We found that EBV-PTLD occurred in 2. Read More

    Early Use of Etanercept for Graft-Versus-Host Disease After Liver Transplant: the Importance of Broad Spectrum Infective Prophylaxis.
    Exp Clin Transplant 2018 Apr 4. Epub 2018 Apr 4.
    From the UOC Anesthesia and Intensive Care Unit, Department of Medicine-DIMED, Padua Hospital, Padua, Italy.
    Graft-versus-host-disease after orthotopic liver transplant is a rare and life-threatening complication. The diagnosis is challenging and usually confirmed by chimerism and skin biopsies. The most common cause of death is sepsis (60%), and broad-spectrum antibiotics and antifungal prophylaxis are strongly recommended. Read More

    Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis.
    Blood Adv 2018 Apr;2(7):777-786
    Department of BMT, Great Ormond Street Hospital for Children, National Health Service (NHS) Foundation Trust, London, United Kingdom.
    Patients with juvenile idiopathic arthritis (JIA) can experience a severe disease course, with progressive destructive polyarthritis refractory to conventional therapy with disease-modifying antirheumatic drugs including biologics, as well as life-threatening complications including macrophage activation syndrome (MAS). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative immunomodulatory strategy for patients with such refractory disease. We treated 16 patients in 5 transplant centers between 2007 and 2016: 11 children with systemic JIA and 5 with rheumatoid factor-negative polyarticular JIA; all were either refractory to standard therapy, had developed secondary hemophagocytic lymphohistiocytosis/MAS poorly responsive to treatment, or had failed autologous HSCT. Read More

    Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies.
    Leuk Lymphoma 2018 Apr 4:1-6. Epub 2018 Apr 4.
    a Department of Pharmacy Services, VCU School of Pharmacy , Virginia Commonwealth University Health , Richmond , VA , USA.
    Allogeneic hematopoietic cell transplantation (HCT) is a curative option for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), but carries a high risk of relapse. This retrospective review evaluates the effectiveness of maintenance azacitidine in high-risk AML and MDS patients to reduce the probability of relapse. Twenty-five patients who received maintenance azacitidine were matched to historical controls in a two-to-one ratio based on diagnosis, donor type, conditioning regimen intensity, and age. Read More

    Environmental Enteropathy in Undernourished Pakistani Children: Clinical and Histomorphometric Analyses.
    Am J Trop Med Hyg 2018 Apr 2. Epub 2018 Apr 2.
    Department of Paediatrics and Child Health, Aga Khan University, Karachi, Pakistan.
    Despite nutrition interventions, stunting thought to be secondary to underlying environmental enteropathy (EE) remains pervasive among infants residing in resource-poor countries and remains poorly characterized. From a birth cohort of 380 children, 65 malnourished infants received 12 weeks of nutritional supplementation with ready-to-use therapeutic food (RUTF). Eleven children with insufficient response to RUTF underwent upper endoscopy with duodenal biopsies, which were compared with U. Read More

    Risks and outcomes of invasive fungal infections in pediatric allogeneic hematopoietic stem cell transplant recipients receiving fluconazole prophylaxis: a multicenter cohort study by the Turkish Pediatric Bone Marrow Transplantation Study Group.
    Med Mycol 2018 Mar 27. Epub 2018 Mar 27.
    Department of Pediatric Hematology&Oncology and BMT Unit, Medical Park Antalya Hospital, Antalya.
    Invasive fungal infections (IFIs) are a major cause of infection-related morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Data from pediatric settings are scarce. To determine the incidence, risk factors and outcomes of IFIs in a 180-day period post-transplantation, 408 pediatric patients who underwent allogeneic HSCT were retrospectively analyzed. Read More

    The devil is in the details: retention of recipient group A type 5 years after a successful allogeneic bone marrow transplant from a group O donor.
    Immunohematology 2018 Jan;33(1):19-22
    Michigan Medicine University of Michigan Ann Arbor, MI.
    Conclusions: ABO-incompatible (ABOi) hematopoietic stem cell transplants (HSCTs) can present challenges in the blood bank. During transplantation, patients receive components that are ABO-compatible with both the donor graft and recipient; this practice can strain group O red blood cell (RBC) inventories.1 In addition, there are risks for acute hemolysis at the time of infusion and in the early post-transplant period. Read More

    Amotosalen/UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host disease.
    Transfusion 2018 Apr 2. Epub 2018 Apr 2.
    Cerus Corporation, Concord, California.
    Introduction: Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare complication after transfusion of components containing viable donor T cells. Gamma irradiation with doses that stop T-cell proliferation is the predominant method to prevent TA-GVHD. Treatment with pathogen inactivation methodologies has been found to also be effective against proliferating white blood cells, including T cells. Read More

    HLA-inferred extended haplotype disparity level is more relevant than the level of HLA mismatch alone for the patients survival and GvHD in T cell-replate hematopoietic stem cell transplantation from unrelated donor.
    Hum Immunol 2018 Mar 29. Epub 2018 Mar 29.
    Department of Clinical Immunology, L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland; Lower Silesian Center for Cellular Transplantation with National Bone Marrow Donor Registry, Wrocław, Poland.
    Serious risks in unrelated hematopoietic stem cell transplantation (HSCT) including graft versus host disease (GvHD) and mortality are associated with HLA disparity between donor and recipient. The increased risks might be dependent on disparity in not-routinely-tested multiple polymorphisms in genetically dense MHC region, being organized in combinations of two extended MHC haplotypes (Ehp). We assessed the clinical role of donor-recipient Ehp disparity levels in N = 889 patients by the population-based detection of HLA allele phase mismatch. Read More

    1 OF 595